Insmed Shares Climb 1.09% to 52-Week High as Analysts Boost Targets, Volume Ranks 492nd

Insmed (INSM) closed on September 8, 2025, with a 1.09% gain, reaching a 52-week high of $146.91 per share. The stock traded with a volume of $230 million, ranking 492nd in market activity. Analyst activity has intensified following recent regulatory and financial developments.

Following Q2 2025 earnings, Guggenheim upgraded its price target to $172 with a "Buy" rating, citing FDA approval for Brinsupri in non-cystic fibrosis bronchiectasis. Morgan Stanley similarly raised its target to $144, emphasizing the commercial potential of brensocatib. Truist Securities adjusted its price target to $139, highlighting the broad label approval of Brinsupri as a catalyst for multi-billion-dollar revenue opportunities.

H.C. Wainwright doubled its price target to $240, positioning Insmed as a potential peer to Genentech and Seagen. William Blair initiated coverage with an "Outperform" rating, noting the company's robust clinical and commercial execution across its portfolio, including Arikayce and TPIP. These analyst actions reflect growing confidence in Insmed’s market positioning and drug pipeline.

To set up this back-test robustly I need to clarify a couple of implementation details: 1. Market universe • Should we rank all listed U.S. equities each day, or restrict the universe (e.g., S&P 500 constituents, NASDAQ only, etc.)? 2. Trade execution convention • Buy time: at that day’s close, or at next day’s open? • Sell time: the following session’s close (one full trading day later) or the same day’s close? 3. Transaction costs & slippage • Do you want to include brokerage commission and/or a slippage assumption? 4. Weighting method • Equal-weight each of the 500 names, or volume-weighted / market-cap-weighted? 5. Benchmark (optional) • If you’d like the back-test to compare against a benchmark (e.g., SPY), let me know. Once I have these details I can run the back-test.